Skip to content
ppharmaranks
Menu

GLEEVEC vs IMKELDI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 14, 2026·How we rate

Rating

70/100
New

Pharmacy pays

~$25.80 /30
~$25.80 /30

Type

RX
RX

Active ingredient

IMATINIB MESYLATE
IMATINIB MESYLATE

Dosage forms

Tablet
Solution

Drug class

Kinase Inhibitor
Kinase Inhibitor

Boxed warning

None
None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome
Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

Which is cheaper, Gleevec or Imkeldi?

Pharmacies pay about the same to acquire either one — roughly $25.80 for a 30-count supply, per the CMS NADAC survey. That is not what you will be charged: your price is set by your insurer and the pharmacy, not by what the drug cost them.

What is the difference between Gleevec and Imkeldi?

Both Gleevec and Imkeldi share the active ingredient Imatinib Mesylate.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.